Prestige BioPharma Limited
KSC: 950210.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- So-Yeon Park
- Employees
- 54
- Headquarters
- Singapore, Singapore
- IPO year
- 2021
- Market cap
- ₩480.8B
- Website
- https://www.prestigebiopharma.com
Loading 950210…
Loading profile data…Frequently asked questions about 950210
What does Prestige BioPharma Limited (950210.KS) do?
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is a...
Where does 950210.KS trade?
Prestige BioPharma Limited (950210.KS) trades on the Korea Exchange.
What sector is 950210.KS in?
Prestige BioPharma Limited (950210.KS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prestige BioPharma Limited?
So-Yeon Park is the chief executive officer of Prestige BioPharma Limited (950210.KS).
Where is Prestige BioPharma Limited headquartered?
Prestige BioPharma Limited is headquartered in Singapore.
Does 950210.KS pay a dividend?
Prestige BioPharma Limited (950210.KS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 950210.KS go public?
Prestige BioPharma Limited (950210.KS) completed its initial public offering in 2021.